Navigation Links
Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
Date:8/19/2010

RADNOR, Pa., Aug. 19 /PRNewswire/ -- The following statement was issued today by the law firm of Barroway Topaz Kessler Meltzer & Check, LLP:

Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Northern District of California on behalf of purchasers of the securities of SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) ("SciClone" or the "Company"), who purchased or otherwise acquired SciClone's securities between May 11, 2009 and August 10, 2010, inclusive (the "Class Period").

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Barroway Topaz Kessler Meltzer & Check, LLP (Darren J. Check, Esq. or D. Seamus Kaskela, Esq.) toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at info@btkmc.com.

The Complaint charges SciClone and certain of its officers with violations of the Securities Exchange Act of 1934. SciClone engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in the People's Republic of China and internationally.  More specifically, the Complaint alleges that the Company failed to disclose and misrepresented the following material adverse facts which were known to defendants or recklessly disregarded by them: (1) that defendants had propped up the Company's results by manipulating SciClone's sales abroad by allegedly engaging in illegal and improper sales behavior that eventually caused the Company to become the subject of investigations by the Securities Exchange Commission ("SEC") and Department of Justice ("DOJ") for violations of the Foreign Corrupt Practices Act ("FCPA"); (2) that SciClone had inadequate systems of internal operational or financial controls, such that SciClone's reported financial statements were true, accurate, or reliable; (3) the Company's financial statements and reports were not prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and SEC rules; and (4) the defendants lacked any reasonable basis to claim that SciClone was operating according to plan, or that SciClone could achieve guidance sponsored and/or endorsed by defendants.

SciClone's principal product is ZADAXIN which is used for the treatment of hepatitis B and hepatitis C viruses and certain cancers, as well as for use as a vaccine adjuvant or as a chemotherapy adjuvant for cancer patients with weakened immune systems.  Throughout the Class Period, SciClone claimed to have commercialization rights for DC Bead, a product candidate for the treatment of advanced liver cancer in China, as well as for ondansetron RapidFilm, an oral thin film formulation of ondansetron to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery in China and Vietnam. As investors ultimately learned, the Company's expansion in China, as well as its representations concerning its systems of controls and procedures, were patently untrue.  The truth later emerged that the defendants were allegedly engaged in illegal and improper sales and marketing activities in China which  ultimately caused the Company to become the focus of a joint investigation by the SEC and the DOJ for possible violations of the FCPA. On this news, shares of the Company's shares declined almost 30% in the single trading day, on unusually heavy trading volume.  

Plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of Barroway Topaz Kessler Meltzer & Check which prosecutes class actions in both state and federal courts throughout the country.  Barroway Topaz Kessler Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.

For more information about Barroway Topaz Kessler Meltzer & Check, or for additional information about participating in this action, please visit www.btkmc.com.

If you are a member of the class described above, you may, not later than October 12, 2010, move the Court to serve as lead plaintiff of the class, if you so choose.  A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff.  Any member of the purported class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.  CONTACT:Barroway Topaz Kessler Meltzer & Check, LLPDarren J. Check, Esq.D. Seamus Kaskela, Esq.280 King of Prussia RoadRadnor, PA 190871-888-299-7706 (toll free) or 1-610-667-7706Or by e-mail at info@btkmc.com
'/>"/>

SOURCE Barroway Topaz Kessler Meltzer & Check, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River
2. Sinovac Holds 2010 Annual Meeting of Shareholders
3. United American Healthcare Corporation Announces Change to Meeting Date for Annual Meeting of Shareholders
4. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
5. Sinovac Schedules 2010 Annual Meeting of Shareholders
6. Hospira Highlights a Year of Significant Progress at Its 2010 Annual Meeting of Shareholders
7. Medco Announces Webcast for Annual Meeting of Shareholders
8. NeoStem Announces Warrant Exercise by Principal Shareholder
9. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
10. CEL-SCI Corporation Releases Letter to Shareholders
11. Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):